1
|
Clément G, Puisieux S, Pellerin D, Brais B, Bonnet C, Renaud M. Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia. Rev Neurol (Paris) 2024:S0035-3787(24)00486-7. [PMID: 38609751 DOI: 10.1016/j.neurol.2024.03.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 03/18/2024] [Accepted: 03/25/2024] [Indexed: 04/14/2024]
Abstract
Genetic cerebellar ataxias are still a diagnostic challenge, and yet not all of them have been identified. Very recently, in early 2023, a new cause of late-onset cerebellar ataxia (LOCA) was identified, spinocerebellar ataxia 27B (SCA27B). This is an autosomal dominant ataxia due to a GAA expansion in intron 1 of the FGF14 gene. Thanks to the many studies carried out since its discovery, it is now possible to define the clinical phenotype, its particularities, and the progression of SCA27B. It has also been established that it is one of the most frequent causes of LOCA. The core phenotype of the disease consists of slowly progressive late-onset ataxia with cerebellar syndrome, oculomotor disorders including downbeat nystagmus, and episodic symptoms such as diplopia. Therapeutic approaches have been proposed, including acetazolamide, and 4-aminopyridine, the latter with a better benefit/tolerance profile.
Collapse
Affiliation(s)
- G Clément
- Service de neurologie, centre hospitalier régional universitaire de Nancy, hôpital Central, Nancy, France; Inserm-U1256 NGERE, université de Lorraine, Nancy, France.
| | - S Puisieux
- Service de neurologie, centre hospitalier régional universitaire de Nancy, hôpital Central, Nancy, France; Inserm-U1256 NGERE, université de Lorraine, Nancy, France.
| | - D Pellerin
- Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada; Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, USA.
| | - B Brais
- Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, QC, Canada.
| | - C Bonnet
- Inserm-U1256 NGERE, université de Lorraine, Nancy, France; Laboratoire de génétique, centre hospitalier régional universitaire de Nancy, hôpitaux de Brabois, Vandœuvre-lès-Nancy, France.
| | - M Renaud
- Service de neurologie, centre hospitalier régional universitaire de Nancy, hôpital Central, Nancy, France; Inserm-U1256 NGERE, université de Lorraine, Nancy, France; Service de génétique clinique, centre hospitalier régional universitaire de Nancy, hôpital d'Enfants, Vandœuvre-Lès-Nancy, France.
| |
Collapse
|
2
|
Renard E, Bonnet C, Di Patrizio M, Schmitt E, Madkaud AC, Chabot C, Kuchenbuch M, Lambert L. Megalencephaly secondary to a novel germline missense variant p.Asp322Tyr in AKT3 associated with growth hormone deficiency and central hypothyroidism: A case report. Am J Med Genet A 2024:e63585. [PMID: 38459620 DOI: 10.1002/ajmg.a.63585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Revised: 02/22/2024] [Accepted: 02/24/2024] [Indexed: 03/10/2024]
Abstract
Germline gain of function variations in the AKT3 gene cause brain overgrowth syndrome with megalencephaly and diffuse bilateral cortical malformations. Here we report a child with megalencephaly, who is a carrier of a novel heterozygous missense variant in the AKT3 gene NM_005465.7:c.964G>T,p.Asp322Tyr. The phenotype of this patient is associated with pituitary deficiencies diagnosed at 2 years of age: growth hormone (GH) deficiency responsible for growth delay and central hypothyroidism. After 6 months of GH treatment, intracranial hypertension was noted, confirmed by the observation of papilledema and increased intracranial pressure, requiring the initiation of acetazolamide treatment and the discontinuation of GH treatment. This is the second reported patient described with megalencephaly and AKT3 gene variant associated with GH deficiency . Other endocrine disorders have also been reported in few cases with hypothyroidism and hypoglycemia. Pituitary deficiency may be a part of the of megalencephaly phenotype secondary to germline variant in the AKT3 gene. Special attention should be paid to growth in these patients and search for endocrine deficiency is necessary in case of growth retardation or hypoglycemia.
Collapse
Affiliation(s)
- E Renard
- Pediatric Endocrinology Unit, Department of Pediatrics, University Hospital of Nancy, Nancy, France
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
| | - C Bonnet
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
- Genetics Laboratory, University Hospital of Nancy, Nancy, France
| | - M Di Patrizio
- Pediatric Endocrinology Unit, Department of Pediatrics, University Hospital of Nancy, Nancy, France
| | - E Schmitt
- Department of Neuroradiology, University Hospital of Nancy, Nancy, France
| | - A C Madkaud
- Department of Ophthalmology, University Hospital of Nancy, Nancy, France
| | - C Chabot
- Pediatric Endocrinology Unit, Department of Pediatrics, University Hospital of Nancy, Nancy, France
| | - M Kuchenbuch
- Department of Pediatric Neurology, University Hospital of Nancy, Nancy, France
- University of Lorraine, Nancy, France
| | - L Lambert
- INSERM UMR_S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
- Department of Clinical Genetics, University Hospital of Nancy, Nancy, France
| |
Collapse
|
3
|
Grosyeux C, Jourdan L, Jellimann JM, Grandmougin A, Bronner M, Lambert L, Bonnet C. ENPP1 homozygous stop-loss variant causing generalized arterial cal cifications of infancy: About a severe neonatal clinical case. Eur J Med Genet 2023:104803. [PMID: 37379879 DOI: 10.1016/j.ejmg.2023.104803] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 05/15/2023] [Accepted: 06/12/2023] [Indexed: 06/30/2023]
Abstract
Generalized Arterial Calcifications of Infancy (GACI) is an extremely rare autosomal recessive genetic condition, mostly due to pathogenic variations in the ENPP1 gene (GACI1, MIM # 208000, ENPP1, MIM *173335). To date 46 likely pathogenic or pathogenic distinct variations in ENPP1 have been described, including nonsense, frameshift, missense, splicing variations, and large deletions. Here we report a case of GACI in a male newborn with a homozygous stop-loss variant in ENPP1 treated in Nancy Regional University Maternity Hospital. Based on proband main clinical signs, clinical exome sequencing was performed and showed a deletion of one nucleotide leading to frameshift and stop-loss (NM_006208.3 (ENPP1):c.2746del,p.(Thr916Hisfs*23)). Clinical presentation is characterized by primary neonatal arterial hypertension resulting in hypertrophic cardiomyopathy decompensated by three cardiogenic shocks and a neonatal deep right sylvian stroke. The child died at 24 days of life. This is the first report of a pathogenic stop-loss variant in ENPP1. It is an opportunity to remind clinicians of GACI disease, a rare and severe etiology in neonates with severe hypertension, and possibility of bisphosphonates therapy.
Collapse
Affiliation(s)
- C Grosyeux
- : Soins Intensifs et Réanimation Néonatals, Pôle Enfants-néonatologie, Maternité régionale Universitaire, Nancy, France
| | - L Jourdan
- : Soins Intensifs et Réanimation Néonatals, Pôle Enfants-néonatologie, Maternité régionale Universitaire, Nancy, France
| | - J-M Jellimann
- : Soins Intensifs et Réanimation Néonatals, Pôle Enfants-néonatologie, Maternité régionale Universitaire, Nancy, France
| | - A Grandmougin
- : Service de radiologie, Hôpital d'enfants, CHRU de Nancy, France
| | - M Bronner
- : Laboratoire de Génétique, Pôle Laboratoires, CHRU de Nancy, France
| | - L Lambert
- : Inserm U1256, Université de Lorraine, France; : Service de Génétique Clinique, Pôle Enfants, CHRU de Nancy, France
| | - C Bonnet
- : Laboratoire de Génétique, Pôle Laboratoires, CHRU de Nancy, France; : Service de Génétique Clinique, Pôle Enfants, CHRU de Nancy, France.
| |
Collapse
|
4
|
Ruiz M, González S, Bonnet C, Deng SX. Extracellular miR-6723-5p could serve as a biomarker of limbal epithelial stem/progenitor cell population. Biomark Res 2022; 10:36. [PMID: 35642012 PMCID: PMC9153202 DOI: 10.1186/s40364-022-00384-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2022] [Accepted: 05/16/2022] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Dysfunction or loss of limbal stem cells can result in limbal stem cell deficiency (LSCD), a disease that cause corneal opacity, pain, and loss of vision. Cultivated limbal epithelial transplantation (CLET) can be used to restore stem cell niche homeostasis and replenish the progenitor pool. Transplantation has been reported with high success rate, but there is an unmet need of prognostic markers that correlate with clinical outcomes. To date, the progenitor content in the graft is the only parameter that has been retrospectively linked to success. METHODS In this study, we investigate extracellular micro RNAs (miRNAs) associated with stem/progenitor cells in cultivated limbal epithelial cells (cLECs). Using micro RNA sequencing and linear regression modelling, we identify a miRNA signature in cultures containing high proportion of stem/progenitor cells. We then develop a robust RNA extraction workflow from culture media to confirm a positive miRNA correlation with stem/progenitor cell proportion. RESULTS miR-6723-5p is associated with cultures containing high proportion of stem/progenitor cells, and is detected in the basal layer of corneal epithelium. CONCLUSIONS These results indicate that miR-6723-5p could potentially serve as a stem/progenitor cell marker in cLECs.
Collapse
Affiliation(s)
- M. Ruiz
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
| | - S. González
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
| | - C. Bonnet
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
- Cornea Department, Paris University, Cochin Hospital, AP-HP, F-75014 Paris, France
| | - S. X. Deng
- Cornea Division, Stein Eye Institute, University of California, 100 Stein Plaza, Los Angeles, CA 90095 USA
| |
Collapse
|
5
|
Amat L, Morel O, Diligent C, Bonnet C, Agopiantz M. [Systematic karyotyping before ICSI: A necessary procedure? Analysis of case studies in the Nancy University Hospital Fertility Centre]. Gynecol Obstet Fertil Senol 2022; 50:314-321. [PMID: 34990881 DOI: 10.1016/j.gofs.2021.12.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Revised: 11/30/2021] [Accepted: 12/19/2021] [Indexed: 06/14/2023]
Abstract
INTRODUCTION A constitutional karyotype is often assayed for the couple before ICSI management. The objective of this study was to assess the prevalence of chromosomal abnormality in an infertile population, the impact on the care of couples and its cost. METHODS A single-center retrospective study was carried out at the Fertility Center of the University Hospital of Nancy, including all infertile couples who underwent a karyotype analysis from June 2009 to December 2016. RESULTS 1252 couples were included. 7.9% had at least one abnormal karyotype. A change in care affected 22% of these couples, i.e. 1.7% of the total population. 9% of couples with karyotype abnormality underwent PGD. In the male population, the percentage of abnormal spermograms is significantly higher in the group with karyotype abnormality compared to the control group (85.7% vs. 46.5%, P<0.001). DISCUSSION The constitutional karyotype, due to its high economic and human cost, and limited interest, is a screening method for chromosomal abnormalities that has no place systematically before performing IVF. The future lies in the restriction of the indications for prescribing the karyotype as well as in the realization of PGS in targeted situations.
Collapse
Affiliation(s)
- L Amat
- Service de médecine de la reproduction, CHRU de Nancy-site maternité, université de Lorraine, 10, rue du Dr-Heydenreich, 54000 Nancy, France; Service de gynécologie médicale, CHRU de Nancy, université de Lorraine, Nancy, France
| | - O Morel
- Service de gynécologie-obstétrique, CHRU de Nancy, université de Lorraine, Nancy, France
| | - C Diligent
- Laboratoire de biologie de la reproduction, CHRU de Nancy, université de Lorraine, Nancy, France
| | - C Bonnet
- Laboratoire de génétique, CHRU de Nancy, université de Lorraine, Vandœuvre-lès-Nancy, France; Inserm U1256, université de Lorraine, Vandœuvre-lès-Nancy, France
| | - M Agopiantz
- Service de médecine de la reproduction, CHRU de Nancy-site maternité, université de Lorraine, 10, rue du Dr-Heydenreich, 54000 Nancy, France; Inserm U1256, université de Lorraine, Vandœuvre-lès-Nancy, France.
| |
Collapse
|
6
|
Salacroup C, David C, Fayemendy P, Misset B, Migolatiev M, Bonhommo S, Bonnet C, Calmel N, Charron L, Rouchaud A, Deluche E, Jésus P. Étude de la sarcopénie selon les critères de masse, de force et de fonction musculaire, au diagnostic de cancer du pancréas : impact sur la survie. NUTR CLIN METAB 2022. [DOI: 10.1016/j.nupar.2021.12.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Simões J, Moran D, Edwards S, Bonnet C, Lopez-Sebastian A, Chemineau P. Editorial: Sustainable livestock systems for high producing animals. Animal 2021; 15 Suppl 1:100371. [PMID: 34688563 DOI: 10.1016/j.animal.2021.100371] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Revised: 08/23/2021] [Accepted: 08/26/2021] [Indexed: 12/16/2022] Open
Affiliation(s)
- J Simões
- Departamento de Ciências Veterinárias, Universidade de Trás-os-Montes e Alto Douro, Quinta de Prados, 5000-801 Vila Real, Portugal.
| | - D Moran
- Global Academy of Agriculture and Food Security, The Royal (Dick) School of Veterinary Studies and The Roslin Institute, The University of Edinburgh, Easter Bush Campus, Midlothian EH25 9RG, United Kingdom
| | - S Edwards
- Newcastle Univ, School of Natural & Environmental Sciences, Newcastle Upon Tyne NE1 7RU, UK
| | - C Bonnet
- Toulouse School of Economics, INRAE, University of Toulouse I Capitole, 1 place de l'Université, 31080 Toulouse Cedex 6, France
| | - A Lopez-Sebastian
- Spanish Natl Inst Agr & Food Res & Technol INIA, Dept Anim Reprod, Madrid 28040, Spain
| | - P Chemineau
- UMR Physiologie de la Reproduction et des Comportements, INRAE, CNRS, IFCE, Université de Tours, 37380 Nouzilly, France; World Association of Animal Production (WAAP), Via Tomassetti, 3, 00161 Roma, Italy
| |
Collapse
|
8
|
Sebuhyan M, Crichi B, Deville L, Le Maignan C, Bonnet C, Marjanovic Z, Rueda J, Bensaoula O, Ndour A, Frere C, Madeleine I, Farge D. Patient education program at the forefront of cancer-associated thrombosis care. J Med Vasc 2021; 46:215-223. [PMID: 34862015 DOI: 10.1016/j.jdmv.2021.08.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Accepted: 08/01/2021] [Indexed: 06/13/2023]
Abstract
INTRODUCTION Treatment of cancer-associated thrombosis (CAT) requires specific approaches, although it is well codified in most cases. Current national and international (International Initiative on Cancer and Thrombosis, ITAC) Clinical Practice Guidelines (CPG) recommend the use of low-molecular-weight heparin (LMWH) over 6 months as first treatment option, and anticoagulation should be maintained thereafter as long as cancer is active. Since compliance improves when patients understand their disease and related treatments, we created a dedicated patient education program (PEP) for CAT, aiming to improve quality of care. METHODS Retrospective analysis of all patients who voluntarily joined the PEP for CAT from 2014 to 2020. RESULTS In total, 182 cancer patients (median age, 64.9 years) were included, 53.3% with metastatic disease. A total of 528 PEP sessions (median, 3 per patient) were delivered. After PEP completion, the rate of self-injections or those performed at home by a relative had increased from 49.1% to 59.8% (P=0.05). Quality of life had improved significantly (P=0.025) and 90.0% of patients reported adhering to anticoagulant therapy. CONCLUSION Implementation of a structured and personalized PEP for CAT is feasible, allowing to improve cancer patient empowerment, adherence to CAT treatment and quality of life. The Groupe francophone et cancer (GFTC) members aim at facilitating access to CAT-PEP for both patients and caregivers and use of the multi-language ITAC-CPG mobile app (free access: www.itaccme.com) to improve the care and quality of life of patients with CAT.
Collapse
Affiliation(s)
- M Sebuhyan
- Groupe francophone thrombose et cancer, Paris, France; Department of Clinical Physiology, Lariboisière Hospital, AP-HP, Paris, France.
| | - B Crichi
- Groupe francophone thrombose et cancer, Paris, France; Department of Internal Medicine (UF 04), CRMR MATHEC, maladies auto-immunes et thérapie cellulaire, Saint-Louis Hospital, AP-HP, Paris, France
| | - L Deville
- Pharmacy Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - C Le Maignan
- Groupe francophone thrombose et cancer, Paris, France; Department of Internal Medicine (UF 04), CRMR MATHEC, maladies auto-immunes et thérapie cellulaire, Saint-Louis Hospital, AP-HP, Paris, France
| | - C Bonnet
- Department of Medical Oncology, Saint-Louis Hospital, AP-HP, Paris, France
| | - Z Marjanovic
- Groupe francophone thrombose et cancer, Paris, France; Department of Hematology, Saint-Antoine Hospital, AP-HP, Paris, France
| | - J Rueda
- Groupe francophone thrombose et cancer, Paris, France; Department of Internal Medicine, Hospital Universitario Rey-Juan-Carlos, Madrid, Spain
| | - O Bensaoula
- Groupe francophone thrombose et cancer, Paris, France; Department of Medical Oncology CLCC Curie Institute, centre Rene-Huguenin, Saint Cloud, France
| | - A Ndour
- Groupe francophone thrombose et cancer, Paris, France; Department of Internal Medicine (UF 04), CRMR MATHEC, maladies auto-immunes et thérapie cellulaire, Saint-Louis Hospital, AP-HP, Paris, France
| | - C Frere
- Groupe francophone thrombose et cancer, Paris, France; Inserm UMRS_1166, Department of Hematology, Institute of Cardiometabolism And Nutrition, GRC 27 GRECO, Pitié-Salpêtrière Hospital, Sorbonne université, AP-HP, Paris, France
| | - I Madeleine
- Pharmacy Department, Saint-Louis Hospital, AP-HP, Paris, France
| | - D Farge
- Groupe francophone thrombose et cancer, Paris, France; Department of Internal Medicine (UF 04), CRMR MATHEC, maladies auto-immunes et thérapie cellulaire, Saint-Louis Hospital, AP-HP, Paris, France; EA 3518, institut universitaire d'hématologie, université de Paris, Paris, France.
| |
Collapse
|
9
|
Sibon D, Bisig B, Bonnet C, Bachy E, Cavalieri D, Fataccioli V, Drieux F, Bruneau J, Lemonnier F, Bossard C, Bouabdallah K, Parrens M, Damaj G, Tournilhac O, Jais JP, Gaulard P, de Leval L. IMPACT OF DUSP22 REARRANGEMENT ON THE PROGNOSIS OF SYSTEMIC ALK‐NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA: A LYSA AND TENOMIC STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.137_2880] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- D Sibon
- Necker University Hospital, Hematology Paris France
| | - B Bisig
- Lausanne University Hospital, Pathology Lausanne Switzerland
| | - C Bonnet
- Liège University Hospital, Clinical Hematology Unit Liège Belgium
| | - E Bachy
- Lyon‐Sud University Hospital, Hematology Pierre‐Bénite France
| | - D Cavalieri
- Clermont‐Ferrand University Hospital, Hematology Clermont‐Ferrand France
| | - V Fataccioli
- Mondor University Hospital, Pathology Créteil France
| | - F Drieux
- Henri Becquerel Cancer Center, Pathology Rouen France
| | - J Bruneau
- Necker University Hospital, Pathology Paris France
| | - F Lemonnier
- Mondor University Hospital, Hematology Créteil France
| | - C Bossard
- Nantes University Hospital, Pathology Nantes France
| | - K Bouabdallah
- Haut‐Lévêque University Hospital, Hematology Bordeaux France
| | - M Parrens
- Haut‐Lévêque University Hospital, Pathology Bordeaux France
| | - G Damaj
- Caen University Hospital, Hematology Caen France
| | - O Tournilhac
- Clermont‐Ferrand University Hospital, Hematology Clermont‐Ferrand France
| | - J. P Jais
- Necker University Hospital, Statistics Paris France
| | - P Gaulard
- Mondor University Hospital, Pathology Créteil France
| | - L de Leval
- Lausanne University Hospital, Pathology Lausanne Switzerland
| |
Collapse
|
10
|
Bologna S, Vander Borght T, Briere J, Ribrag V, Damaj GL, Thieblemont C, Feugier P, Peyrade F, Lebras L, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquieres H, Becker S, Olivier P, Fabiani B, Tilly H, Haioun C, Bastie JN. EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL. Hematol Oncol 2021. [DOI: 10.1002/hon.5_2879] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S Bologna
- Hématologie Privée Nancéienne 54 Essey lès Nancy France
| | | | - J Briere
- CHU Henri Mondor 94 Créteil France
| | - V Ribrag
- Institut Gustave Roussy 94 Villejuif France
| | | | | | - P Feugier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - F Peyrade
- Centre Antoine Lacassagne 06 Nice France
| | - L Lebras
- Centre Léon Berard 69 Lyon, France
| | - D Coso
- Institut Paoli Calmette 13 Marseille France
| | - D Sibon
- Hôpital Necker-Enfants Malades 75 Paris France
| | | | | | | | - S Becker
- Centre Henri Becquerel 76 Rouen France
| | - P Olivier
- CHRU Nancy 54 Vandoeuvre lès Nancy France
| | - B Fabiani
- Hopital Saint Antoine 75 Paris France
| | - H Tilly
- Centre Henry Becquerel 76 Rouen France
| | - C Haioun
- Hopital Henri Mondor 94 Créteil France
| | | |
Collapse
|
11
|
Cavalieri D, Tournilhac O, Missiglia E, Bonnet C, Ledoux‐Pilon A, Bisig B, Cairoli A, Poullot E, Fataccioli V, Parrens M, Copin MC, Gutierrez FL, Xerri L, Bossard C, Wind R, Drieux F, Lhomme F, Daniel A, Clément‐Filliatre L, Lemmonier F, Morel P, Noël R, Brotelle T, Glaisner S, Sibon D, Yamani A, Bologna S, Queru K, Damaj G, Letailleur V, Villemagne B, Fleck E, Dupont E, Tchernonog E, Monjanel H, Wilde V, Vallois D, Gaulard P, Leval L. MONOMORPHIC EPITHELIOTROPIC INTESTINAL T‐CELL LYMPHOMA (MEITL): CLINICO‐PATHOLOGICAL ANALYSIS OF A MULTICENTER EUROPEAN COHORT. Hematol Oncol 2021. [DOI: 10.1002/hon.44_2879] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
12
|
Hübel K, Scholz CW, Luminari S, Salar A, Wahlin BE, Gopal AK, Bonnet C, Trneny M, Paneesha S, Manzke O, Seguy F, Li D, Sehn LH. INMIND: A PHASE 3 STUDY OF TAFASITAMAB + LENALIDOMIDE AND RITUXIMAB VS PLACEBO + LENALIDOMIDE AND RITUXIMAB FOR RELAPSED/REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.175_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- K. Hübel
- University Hospital Cologne Department of Internal Medicine I Oncology and Hematology Cologne Germany
| | - C. W. Scholz
- Vivantes Klinikum Am Urban Department of Hematology and Oncology Berlin Germany
| | - S. Luminari
- Azienda USL‐IRCCS di Reggio Emilia Hematology Unit Reggio Emilia Italy
| | - A. Salar
- Hospital del Mar‐IMIM Department of Haematology Barcelona Spain
| | - B. E. Wahlin
- Unit of Hematology Karolinska Institute Department of Medicine Stockholm Sweden
| | - A. K. Gopal
- University of Washington Medicine Division of Medical Oncology Seattle Washington USA
| | - C. Bonnet
- Centre Hospitalier Universitaire University of Liège Clinical Hematology Liège Belgium
| | - M. Trneny
- First Faculty of Medicine Charles University General Hospital First Department of Medicine Prague Czech Republic
| | - S. Paneesha
- University Hospitals Birmingham NHS Foundation Trust Hematology Birmingham UK
| | - O. Manzke
- Incyte Biosciences International Sàrl Clinical Development Morgues Switzerland
| | - F. Seguy
- Incyte Biosciences International Sàrl Clinical Development Morgues Switzerland
| | - D. Li
- Incyte Corporation Biostatistics Wilmington Delaware USA
| | - L. H. Sehn
- BC Cancer Centre for Lymphoid Cancer and The University of British Columbia Division of Medical Oncology Vancouver Canada
| |
Collapse
|
13
|
Camus V, Rossi C, Sesques P, Lequesne J, Tonnelet D, Haioun C, Durot E, Willaume A, Gauthier M, Moles‐Moreau M, Antier C, Lazarovici J, Monjanel H, Bernard S, Tardy M, Besson C, Lebras L, Choquet S, Le Du K, Bonnet C, Bailly S, Damaj G, Laribi K, Maisonneuve H, Houot R, Chauchet A, Jardin F, Traverse‐Glehen A, Decazes P, Becker S, Berriolo‐Riedinger A, Tilly H. OUTCOMES AFTER FIRST‐LINE IMMUNOCHEMOTHERAPY FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS: A LYSA STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.50_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- V. Camus
- Centre Henri Becquerel Department of Hematology Rouen France
| | - C. Rossi
- Dijon University Hospital Hematology Dijon France
| | - P. Sesques
- CHU Lyon Sud, Hematology Pierre‐Bénite France
| | - J. Lequesne
- Centre Henri Becquerel Clinical Research Unit Rouen France
| | - D. Tonnelet
- Centre Henri Becquerel Department of Nuclear Medicine Rouen France
| | - C. Haioun
- CHU Mondor, Hematology Créteil France
| | - E. Durot
- CHU Reims Hematology Reims France
| | | | | | | | | | | | | | | | - M. Tardy
- Centre Antoine Lacassagne Hematology Nice France
| | - C. Besson
- Centre Hospitalier de Versailles Hematology Le Chesnay France
| | - L. Lebras
- Centre Leon Berard Hematology Lyon France
| | - S. Choquet
- CHU La pitié salpetriere Hematology Paris France
| | - K. Le Du
- Clinique Victor Hugo Hematology Le Mans France
| | - C. Bonnet
- Liege University Hospital Hematology Liege Belgium
| | - S. Bailly
- Cliniques Universitaires Saint Luc Hematology Bruxelles Belgium
| | | | - K. Laribi
- CH Le Mans Hematology Le Mans France
| | - H. Maisonneuve
- CH Departemental de Vendée Hematology la Roche sur Yon France
| | - R. Houot
- CHU Rennes Hematology Rennes France
| | | | - F. Jardin
- Centre Henri Becquerel Department of Hematology Rouen France
| | | | - P. Decazes
- Centre Henri Becquerel Department of Nuclear Medicine Rouen France
| | - S. Becker
- Centre Henri Becquerel Department of Nuclear Medicine Rouen France
| | | | - H. Tilly
- Centre Henri Becquerel Department of Hematology Rouen France
| |
Collapse
|
14
|
Gastinne T, Bouabdallah K, Moatti H, Tessoulin B, Shiano del colella JM, Lamy T, Casasnovas O, Borel C, Stamatoullas A, Gac AC, Chaoui D, Feugier P, Delmer A, Bonnet C, Fornecker L, Lazarovici J, Bras F, Ghesquieres H, Meignan M, Traverse Glehen A, Brice P. BRENTUXIMAB VEDOTIN AS CONSOLIDATION TREATMENT IN PATIENTS WITH STAGE I/II CLASSICAL HODGKIN'S LYMPHOMA AND A POSITIVE FDG‐PET AFTER 2 CYCLES OF ABVD: A LYSA PHASE 2 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.111_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- T. Gastinne
- University Hospital of Nantes Hematology Nantes France
| | - K. Bouabdallah
- Hopital Haut‐Levêque Centre Hospitalier Regional Universitaire de Bordeaux Department of Hematology Pessac France
| | - H. Moatti
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| | - B. Tessoulin
- University Hospital of Nantes Hematology Nantes France
| | | | - T. Lamy
- Rennes University Hospital Department of Clinical Hematology MICA Research Unit Rennes France
| | - O. Casasnovas
- University Hospital F Mitterrand and INSERM 1231 Department of Haematology Dijon France
| | - C. Borel
- IUCT‐Oncopole CHU Toulouse Department of Haematology Toulouse France
| | - A. Stamatoullas
- Centre Henri Becquerel Department of Haematology U918 Rouen France
| | - A. C. Gac
- Centre Hospitalier Universitaire de Caen Institut d'hématologie de Basse‐Normandie Caen France
| | - D. Chaoui
- Centre Hospitalier d'Argenteuil Department of Hematology Argenteuil France
| | - P. Feugier
- Nancy University Hospital Department of Clinical Hematology INSERM 1256 Nancy France
| | - A. Delmer
- University Hospital of Reims Department of Haematology Reims France
| | - C. Bonnet
- CHU Liège, Liège Université Campus Universitaire de Sart Tilman Clinical Hematology Unit Liège Belgium
| | - Luc‐M. Fornecker
- Strasbourg University Hospital Department of Clinical Hematology Strasbourg France
| | - J. Lazarovici
- Institut Gustave Roussy Département des Innovations Thérapeutiques et Essais Précoces Villejuif France
| | - F. Bras
- CHU Henri Mondor Department of Hematology Creteil France
| | - H. Ghesquieres
- Hospices Civils de Lyon Centre Hospitalier Lyon‐Sud and Université Claude Bernard Lyon‐1 Department of Haematology Lyon France
| | - M. Meignan
- Hôpital H Mondor LYSA Imaging Creteil France
| | - A. Traverse Glehen
- Centre Hospitalier Lyon‐Sud Hospices Civils de Lyon Pathology Department cedex, France, Lyon France
| | - P. Brice
- Hôpital saint Louis APHP Université Paris 7 Department of Oncohaematology Paris France
| |
Collapse
|
15
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, Gomesda Silva M, Bouabdallah R, Salles G, Bachy E. Corrigendum to 'Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers': [Annals of Oncology Volume 29, Issue 3, March 2018, Pages 715-723]. Ann Oncol 2021; 32:945. [PMID: 33992519 DOI: 10.1016/j.annonc.2021.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Affiliation(s)
- G Fossard
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France
| | - F Broussais
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
| | - I Coelho
- Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
| | - S Bailly
- Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Clermont Auvergne University, Clermont-Ferrand, France
| | | | - E Toussaint
- Hematology Department, CHU de Strasbourg, Strasbourg, France
| | | | - F Le Bras
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - E Willems
- Hematology Department, CHU de Liège, Liège, Belgium
| | - E Tchernonog
- Hematology Department, CHU de Montpellier, Montpellier, France
| | - T Chalopin
- Hematology Department, CHU de Tours, Tours, France
| | - R Delarue
- Hematology Department, CHU Necker Enfants Malades, AP-HP, Paris, France
| | - R Gressin
- Hematology Department, CHU de Grenoble, Grenoble, France
| | - A Chauchet
- Hematology Department, CHU de Besançon, Besançon, France
| | - E Gyan
- Hematology Department, CHU de Tours, Tours, France
| | - G Cartron
- Hematology Department, CHU de Montpellier, Montpellier, France
| | - C Bonnet
- Hematology Department, CHU de Liège, Liège, Belgium
| | - C Haioun
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - G Damaj
- Hematology Institute, CHU de Caen, Caen, France
| | - P Gaulard
- Hematology Department, CHU Henri Mondor, Creteil, France
| | - L Fornecker
- Hematology Department, CHU de Strasbourg, Strasbourg, France
| | - H Ghesquières
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France
| | - O Tournilhac
- Hematology and Cell Therapy Department, Hôpital Estaing, CHU de Clermont-Ferrand, Clermont-Ferrand, France; Clermont Auvergne University, Clermont-Ferrand, France
| | - M Gomesda Silva
- Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal
| | - R Bouabdallah
- Hematology Department, Institut Paoli Calmette, Marseille, France
| | - G Salles
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France
| | - E Bachy
- Hematology Department, CHU Lyon Sud, Hospices Civils de Lyon, Pierre Benite, France; Claude Bernard Lyon 1 University, Lyon, France; Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France.
| |
Collapse
|
16
|
Maquet C, Beguin Y, De Prijck B, Willems E, Servais S, Bonnet C. [Diffuse large B-cell lymphoma: a revolutionary treatment based on genetically-modified immune cells called CAR T cells]. Rev Med Liege 2021; 76:476-481. [PMID: 34080383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Firstline immunochemotherapy cures approximatively 60 % of patients. The prognosis of patients with refractory disease or with relapsed disease within the first two years after the end of treatment is highly unfavourable. Since June 2019, a new third-line treatment with CAR T cells (chimeric antigen receptor T cells) seems to completely modify the prognosis of these patients. A significant proportion of long-lasting complete responses is obtained with this revolutionary treatment. Quick specialized intervention is required for the unique side effects of this therapy.
Collapse
Affiliation(s)
- C Maquet
- Service d'Hématologie, CHU Liège, Belgique
| | - Y Beguin
- Service d'Hématologie, CHU Liège, Belgique
| | | | - E Willems
- Service d'Hématologie, CHU Liège, Belgique
| | - S Servais
- Service d'Hématologie, CHU Liège, Belgique
| | - C Bonnet
- Service d'Hématologie, CHU Liège, Belgique
| |
Collapse
|
17
|
Lebas E, Collins P, Bonnet C, Libon F, Dezfoulian B, Nikkels AF. [Management of mycosis fungoide : focus on brentuximab vedotin]. Rev Med Liege 2021; 76:224-231. [PMID: 33830684] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Recently, brentuximab vedotin (BV) (Adcetris®) obtained the reimbursement in Belgium for the treatment of the primary cutaneous NKT-cell lymphomas mycosis fungoides (MF), large cell anaplastic lymphoma and lymphomatoid papulosis type A. BV is a monoclonal antibody directed against the CD30 expressed on tumoral T cells. The inhibition of this pathway releases the process of apoptosis leading to the cell death of the tumoral cells. BV is reimbursed after the use of another systemic treatment without success and if the number of CD30 positive atypical T-cells is larger than 10 %. BV is administered intravenously every 3 weeks with a dosing of 1,8 mg/kg with a maximum of 16 courses. The response rates exceed 75 %. In some instances, interesting treatment responses have been observed with BV in CD30 negative patients. The principal adverse effects are neutropenia and peripheral neuropathy. Two patients are presented with longstanding multi-resistant MF that were successfully treated with BV.
Collapse
Affiliation(s)
- E Lebas
- ) Service de Dermatologie, CHU Liège, Belgique
| | - P Collins
- Service de Dermatopathologie, CHU Liège, Belgique
| | - C Bonnet
- Service d'Hématologie, CHU Liège, Belgique
| | - F Libon
- ) Service de Dermatologie, CHU Liège, Belgique
| | | | - A F Nikkels
- ) Service de Dermatologie, CHU Liège, Belgique
| |
Collapse
|
18
|
Enjary M, Monnet D, Bonnet C, Brézin AP. Patients' perception of the open-space operating hall for cataract surgery. J Fr Ophtalmol 2021; 44:494-498. [PMID: 33736858 DOI: 10.1016/j.jfo.2020.06.043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 06/23/2020] [Indexed: 11/18/2022]
Abstract
PURPOSE To assess the perception of patients undergoing cataract surgery under topical anesthesia in an open-space operating hall. METHODS The study was set in the department of ophthalmology, Cochin Paris Descartes University Hospital, in a newly built open-space operating hall dedicated to ophthalmic surgery. It was a prospective study of consecutive patients undergoing cataract surgery by 11 surgeons. Our population study comprised 250 patients operated in an open-space operating hall with 3 surgical areas. Only first-eye standard cataract surgeries performed under topical anesthesia were included. Responses to a face-to-face questionnaire administered by a single interviewer to patients before their discharge on the day of their surgery were analyzed. RESULTS Fifty-two patients (21%) knew beforehand that their procedure would take place in an open-space operating hall, 118 (47%) realized that they were in such an environment on the occasion of their surgery and 80 (32%) did not notice. Conversations and noises unrelated to their own surgeries were overheard respectively by 15 (6%) and 37 (15%) patients. Of the 250 patients, 237 (95%) did not report any discomfort associated with the fact that their procedure had been performed in an open-space operating hall. CONCLUSIONS Cataract surgery performed in an open-space setting did not seem to affect the patients' comfort during the procedure.
Collapse
Affiliation(s)
- M Enjary
- Service d'ophtalmologie, hôpital Cochin, université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - D Monnet
- Service d'ophtalmologie, hôpital Cochin, université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - C Bonnet
- Service d'ophtalmologie, hôpital Cochin, université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - A P Brézin
- Service d'ophtalmologie, hôpital Cochin, université Paris-Descartes, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| |
Collapse
|
19
|
Radermecker A, Bonnet C, Lutteri L, Chapelle AC, Petignot S, Lievens I, Caers J. [An illustrative case of the POEMS syndrome]. Rev Med Liege 2021; 76:156-159. [PMID: 33682383] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
POEMS syndrome is a rare and invalidating entity characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and dermatoses. The diagnosis of this condition is often late and challenging due to the heterogeneity of clinical forms. The light chains secreted by the clonal plasmocytes cause overproduction of VEGF (Vascular Endothelial Growth Factor) responsible for the appearance of the clinical manifestations of POEMS. The diagnostic approach is based on different clinical and biological criteria. Patients with a solitary plasmacytoma are candidates for radiotherapy treatment. Patients with diffuse bone involvement or bone marrow infiltration are best treated by systemic drugs. The response to treatment may take several months before clinical and biological improvement. Early diagnosis and dedicated management limit the clinico-functional impact of POEMS.
Collapse
Affiliation(s)
| | - C Bonnet
- Service d'Hématologie, CHU Liège, Belgique
| | - L Lutteri
- Service de Chimie Clinique, CHU Liège, Belgique
| | | | - S Petignot
- Service d'Endocrinologie, CHU Liège, Belgique
| | - I Lievens
- Service de Neurologie, CHU Liège, Belgique
| | - J Caers
- Service d'Hématologie, CHU Liège, Belgique
| |
Collapse
|
20
|
Abstract
Objectif : Cette étude qualitative vise à décrire les effets narratifs d’un protocole d’accompagnement psychooncologique s’appuyant sur les productions picturales d’une proche aidante (Mme Rose, 70 ans) accompagnant son mari atteint d’un cancer incurable.
Matériel et méthode : Il s’agit d’un protocole autour de la figuration picturale de la proche aidante composé de quatre étapes (temps) : l’entretien préliminaire (T1), une première rencontre autour de la création picturale (T2), une seconde rencontre d’approfondissement autour de la création picturale (T3), l’entretien final (T4). Nous avons utilisé le logiciel T-LAB 9.1.3 pour le calcul des associations de mots (cooccurrences) et réalisé une interprétation du récit selon l’approche humaniste/existentielle.
Résultats : Ce dispositif de recherche a permis de montrer les effets narratifs avant et après le travail artistique sur les problématiques psychiques inhérentes au vécu du proche aidant et notamment sur l’angoisse de mort. La dimension romantique du récit semble pouvoir supporter la narration tragique de Mme Rose.
Conclusion : Le « travail psychique avec la production picturale » peut permettre au proche aidant de mettre en figure l’amour et la mort à travers une narration personnelle empruntant à l’univers narratif du romantisme ses enjeux existentiels.
Collapse
|
21
|
Crichi B, Sebuhyan M, Abdallah NA, Montlahuc C, Bonnet C, Villiers S, Maignan CL, Yannoutsos A, Farge D. How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital. J Med Vasc 2020; 45:6S24-6S30. [PMID: 33276940 DOI: 10.1016/s2542-4513(20)30516-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND - The management of venous thromboembolism (VTE) is particularly challenging in patients with cancer who undergo complex treatment protocols. Cancer patients often have comorbidities which may affect the efficacy and safety of anticoagulant treatments. Coordinated multidisciplinary management of these complex cases can help optimize delivery of individualized anticoagulant treatment. AIMS - To describe the multidisciplinary team meeting (MDTM) for the management of VTE in cancer patients at our institution and to document outcomes in these patients. METHODS - Bi-monthly MDTMs attended by different physicians and nurses were established at Saint-Louis Hospital in 2008. We performed a retrospective analysis of all cases discussed between September 2008 and January 2018. RESULTS - Over a 10-year period, 520 patients were discussed a total of 551 times. Their mean age was 63 years with 278 (53%) women. The most frequent primary cancer sites were breast (23%), genitourinary (21 %), hematological (20%), digestive (15%), and lung (9%). Fifty-two percent of patients had metastatic cancer, and 54% of them were receiving chemotherapy. The optimal treatment for pulmonary embolism (17%), deep vein thrombosis (16%), catheter-related thrombosis (20%) or combined events (46%) was discussed. Twenty-three patients (4.4%) were discussed for one VTE recurrence and 4 (0.8%) for 2 recurrences. CONCLUSIONS - A dedicated MDTM for the management of VTE in cancer patients allows to discuss a wide range of clinical scenarios and contributes to optimal adherence to evidence-based clinical practices guidelines. The MDTM evaluation was successfully carried out within a short time-frame of VTE diagnosis and helped optimize individualized treatment plans.
Collapse
Affiliation(s)
- B Crichi
- Internal Medicine, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; Groupe Francophone Thrombose et Cancer, Paris, France
| | - M Sebuhyan
- Internal Medicine, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; Groupe Francophone Thrombose et Cancer, Paris, France
| | - N Ait Abdallah
- Internal Medicine, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; Groupe Francophone Thrombose et Cancer, Paris, France
| | - C Montlahuc
- Clinical Research Unit Lariboisière Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Bonnet
- Department of Medical Oncology, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - S Villiers
- Groupe Francophone Thrombose et Cancer, Paris, France; Department of Anesthesiology, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France
| | - C Le Maignan
- Groupe Francophone Thrombose et Cancer, Paris, France
| | - A Yannoutsos
- Department of Vascular Medicine, Paris Saint-Joseph Hospital Group, Paris, France
| | - D Farge
- Internal Medicine, Autoimmune and Vascular Disease Unit, Saint-Louis Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; Groupe Francophone Thrombose et Cancer, Paris, France; Université de Paris, Paris, France; Department of Medicine, McGill University, Montreal, Québec, Canada.
| |
Collapse
|
22
|
Sebuhyan M, Crichi B, Abdallah NA, Bonnet C, Deville L, Marjanovic Z, Farge D. Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. J Med Vasc 2020; 45:6S31-6S38. [PMID: 33276942 DOI: 10.1016/s2542-4513(20)30517-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Cancer-associated thrombosis (CAT) is the second leading cause of death in cancer patients after tumor progression. The treatment of CAT is challenging because of a high risk of VTE recurrence, a high risk of bleeding, common presence of comorbidities, poly-medication, and potential drug-drug interactions (DDI). Since 2018, direct oral anticoagulants (DOACs) represent a promising therapeutic alternative and have been recently included into the 2019 update of the International Initiative on Thrombosis and Cancer (ITAC-CME) clinical practice guidelines for management of CAT. However, pharmacokinetic studies suggest that concomitant treatment with P-gp or CYP3A4 inhibitors will result in an increased exposure to rivaroxaban and apixaban, but the clinical relevance of these studies is unknown. In addition, there is an important inter-individual variability in drug absorption, distribution, metabolism and elimination, even more in cancer patients. Overall, the risk of pharmacokinetic DDI should be estimated based on several individual (patient age, renal and liver function, number of comedications) and diseases-related factors, including inflammation, sarcopenia, and low body weight. In this context, DDI with clinical implications could be expected with anti-neoplastic agents or supportive care treatments, especially with drugs known to be moderate or strong inhibitors/inducers of CYP3A4 and P-gp. Consequently, in the presence of potential DDIs through CYP3A4, and/or P-gp, LMWHs remain the first-line anticoagulant of choice for the long-term treatment of CAT. Multidisciplinary consultation meetings and therapeutic patient education should be emphasized in the complex management of CAT.
Collapse
Affiliation(s)
- M Sebuhyan
- Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris (APHP), 1 avenue Claude-Vellefaux, 75010 Paris, France.
| | - B Crichi
- Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris (APHP), 1 avenue Claude-Vellefaux, 75010 Paris, France
| | - N Ait Abdallah
- Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris (APHP), 1 avenue Claude-Vellefaux, 75010 Paris, France
| | - C Bonnet
- Service d'oncologie médicale, hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris (APHP), 1 avenue Claude-Vellefaux, 75010 Paris, France.
| | - L Deville
- Service de pharmacie, hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris (APHP), 1 avenue Claude-Vellefaux, 75010 Paris, France
| | - Z Marjanovic
- Service d'hématologie clinique et thérapie cellulaire, hôpital Saint-Antoine, Assistance publique des Hôpitaux de Paris (APHP), 184 rue du Faubourg Saint-Antoine, 75012 Paris, France
| | - D Farge
- Unité de médecine interne : maladies auto-immunes et pathologie vasculaire (UF04), hôpital Saint-Louis, Assistance publique des Hôpitaux de Paris (APHP), 1 avenue Claude-Vellefaux, 75010 Paris, France; Université de Paris, IRSL, EA-3518, Recherche clinique appliquée à l'hématologie, F-75010 Paris, France; Department of Medicine, McGill University, Montreal, QC, Canada.
| |
Collapse
|
23
|
Jamelot M, Pressat-Laffouilhere T, Baciarello G, Dumont C, Bonnet C, Fizazi K, Culine S. 648P Abiraterone and dexamethasone in castration-resistant prostate cancer: Biological response after switch or rechallenge. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
24
|
Abstract
Uveitis is an inflammation of the uveal tissue: iris, ciliary body and choroid. The annual incidence of uveitis in France is low (17/100,000), but visual and therapeutic consequences may be severe. Etiologic investigation is thus a fundamental step in the management of any uveitis. The history plays an important role in the initial evaluation; it must be methodic. The ophthalmologic examination seeks to classify the uveitis by type (granulomatous or not), location (anterior, intermediate or posterior), severity, duration and recurrence. Systemic signs often orient the diagnosis toward a specific cause. The diagnostic approach to uveitis relies on the history, ophthalmologic examination and evaluation of possible extraocular manifestations. Ancillary testing must be prescribed based on the clinical differential diagnosis, without which their yield is very low.
Collapse
Affiliation(s)
- C Bonnet
- Pôle de Paris, service d'ophtalmologie, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg St Jacques, 75014 Paris, France.
| | - A Brézin
- Pôle de Paris, service d'ophtalmologie, hôpital Cochin, université Paris Descartes, 27, rue du Faubourg St Jacques, 75014 Paris, France
| |
Collapse
|
25
|
Couillard F, Guillain L, Cenraud M, Bertin P, Vergne-Salle P, Bonnet C, Couratier P, Magy L, Fauchais A, Ly K. Une fracture vertébrale non traumatique chez un sujet jeune conduisant au diagnostic de stiff person syndrome ! Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.10.279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Demiguel V, Blondel B, Bonnet C, Andler R, Saurel-Cubizolles MJ, Regnault N. Tobacco smoking in pregnant women: fifty years of evolution in France. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz185.438] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Smoking during pregnancy is a major modifiable risk factor for maternal and foetal morbidity. We aimed to describe 1/smoking trends in France between 1972 and 2016, 2/ the factors associated with smoking cessation and reduction during pregnancy in 2016.
Methods
French National Perinatal Surveys are routine surveys based on a representative sample of births (N = 11,733 in 2016). Data were collected in face-to-face interviews in postnatal wards and from the mother’s medical record. Smoking rates before pregnancy and during 3rd trimester were estimated for each study year and characteristics associated with smoking reduction (relative percent change in number of cigarettes smoked before and during pregnancy <50% or ≥ 50%) compared with smoking cessation were analysed using multinomial logistic regression.
Results
After significantly decreasing from 1995 onwards, smoking prevalence stagnates since 2010 both before pregnancy and in the 3rd trimester (30.1% and 16.2%, respectively in 2016). In 2016, 45.8% ceased smoking during pregnancy, 37.2% reduced by ≥ 50% their consumption and 16.9% reduced by < 50% or did not reduce at all. The more cigarettes women smoked before pregnancy, the greater this reduction was (p < 0,001). Moderate reduction (<50%) vs stopping was more frequent in multiparae compared to nulliparae (aOR=2,47 [IC95%:1,93-3,15]) and in women with low education (aOR(<High school vs university graduates)=7,20 [4,78-10,82]) and low income (aOR(<1500€per month/>3000€)=2,30 [1,51-3,50]).
Conclusions
Smoking rates were high before and during pregnancy in France in 2016. Socio-demographic factors should be considered when targeting women most at risk of continuing smoking during pregnancy.
Key messages
After significantly decreasing from 1995 onwards, smoking prevalence stagnates since 2010 both before pregnancy and in the 3rd trimester in France. Supporting female smokers of childbearing age in their attempts to quit and remain non-smokers even after pregnancy is crucial, especially in multiparae and women in poor social condition.
Collapse
Affiliation(s)
- V Demiguel
- Non Communicable Diseases and Trauma Direction, Santé Publique France, St Maurice, France
| | - B Blondel
- INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidem, Centre for Epidemiology and Statistics, Paris Descartes University, Paris, France
| | - C Bonnet
- INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidem, Centre for Epidemiology and Statistics, Paris Descartes University, Paris, France
| | - R Andler
- Prevention and Health Promotion Direction, Santé Publique France, St Maurice, France
| | - M J Saurel-Cubizolles
- INSERM UMR 1153, Obstetrical, Perinatal and Pediatric Epidem, Centre for Epidemiology and Statistics, Paris Descartes University, Paris, France
| | - N Regnault
- Non Communicable Diseases and Trauma Direction, Santé Publique France, St Maurice, France
| |
Collapse
|
27
|
Bonnet C, Amsallem A, Tissot E, Morgny C, Vandel P. Évaluation de l’utilisation d’antipsychotiques injectables à action prolongée (APAP) versus antipsychotiques per os en vie réelle dans le traitement de la schizophrénie. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.04.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
28
|
Morel N, Mehawej H, Bonnet C, Le Guern V, Perard L, Roumier M, Brézin A, Godeau B, Haroche J, Piette J, Costedoat-Chalumeau N. Syndrome catastrophique des antiphospholipides et atteinte du segment postérieur de l’œil. Rev Med Interne 2019. [DOI: 10.1016/j.revmed.2019.03.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
29
|
|
30
|
Belhadj M, Aquino A, Heng J, Kmiotek S, Raël S, Bonnet C, Lapicque F. Current density distributions in polymer electrolyte fuel cells: A tool for characterisation of gas distribution in the cell and its state of health. Chem Eng Sci 2018. [DOI: 10.1016/j.ces.2018.03.055] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
31
|
Arora D, Gérardin K, Raël S, Bonnet C, Lapicque F. Effect of supercapacitors directly hybridized with PEMFC on the component contribution and the performance of the system. J APPL ELECTROCHEM 2018. [DOI: 10.1007/s10800-018-1188-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
32
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Le Bras F, Willems E, Tchernonog E, Chalopin T, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquières H, Tournilhac O, da Silva MG, Bouabdallah R, Salles G, Bachy E. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol 2018; 29:715-723. [DOI: 10.1093/annonc/mdx787] [Citation(s) in RCA: 69] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Baldi I, Engelhardt J, Bonnet C, Bauchet L, Berteaud E, Grüber A, Loiseau H. Epidemiology of meningiomas. Neurochirurgie 2018; 64:5-14. [DOI: 10.1016/j.neuchi.2014.05.006] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 05/15/2014] [Accepted: 07/24/2014] [Indexed: 12/15/2022]
|
34
|
Bartošová O, Bonnet C, Ulmanová O, Šíma M, Perlík F, Růžička E, Slanař O. Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients. J Neural Transm (Vienna) 2017; 125:699-703. [DOI: 10.1007/s00702-017-1829-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2017] [Accepted: 12/12/2017] [Indexed: 11/30/2022]
|
35
|
Morschhauser F, Le Gouill S, Feugier P, Van Den Neste E, Nicolas-Virelizier E, Bijou F, Salles G, Tilly H, Van Eygen K, Van Hoof A, Bonnet C, Haioun C, Bouabdallah R, Fabiani B, Xerri L, Cartron G, Houot R. A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_36] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- F. Morschhauser
- Service des Maladies du Sang; University of Lille; Lille France
| | - S. Le Gouill
- Hematology; Nantes University Hospital; Nantes France
| | - P. Feugier
- Service d'Hématologie; CHU de Nancy - Hôpitaux de Brabois, VANDOEUVRE-LES-NANCY; France
| | - E. Van Den Neste
- Service d'Hématologie; Université Catholique de Louvain Saint Luc; Bruxelles Belgium
| | | | - F. Bijou
- Service d'Hématologie; Institut Bergonié - Centre Régional de Lutte contre le Cancer; Bordeaux France
| | - G.A. Salles
- Service d'Hématologie; CHU Lyon-Sud; Lyon France
| | - H. Tilly
- Service d'Hématologie; Centre Henri Becquerel; Rouen France
| | - K. Van Eygen
- President Kennedylaan 4, AZ Groeninge; Kortrijk Belgium
| | | | - C. Bonnet
- Service d'Hématologie; CHU de Liège; Liège Belgium
| | - C. Haioun
- Unité des Hémopathies Lymphoïdes; Hôpital Henri Mondor; Créteil France
| | - R. Bouabdallah
- Service d'Hématologie; Institut Paoli Calmettes; Marseille France
| | - B. Fabiani
- Service d'Anatomie-Pathologie; Hôpital Saint-Antoine; Paris France
| | - L. Xerri
- Département de Bio-Pathologie; Institut Paoli Calmettes; Marseille France
| | - G. Cartron
- Service d'Hématologie; CHU Saint-Eloi; Montpellier France
| | - R. Houot
- Service d'Hématologie; CHU Pontchaillou; Rennes France
| |
Collapse
|
36
|
Abstract
Vogt-Koyanagi-Harada (VKH) disease is defined as a severe bilateral, chronic granulomatous panuveitis associated with serous retinal detachments, disk edema, and vitritis, with central nervous system, auditory, and integumentary manifestations. It is an autoimmune inflammatory condition mediated by T cells that target melanocytes in individuals genetically susceptible to the disease. Vogt-Koyanagi-Harada disease presents clinically in 4 different phases: prodromal, acute inflammatory, chronic, and recurrent, with extraocular manifestations including headache, meningitis, hearing loss, poliosis, and vitiligo. Optical coherence tomography (OCT) allows earlier diagnosis of VKH disease by revealing heterogeneous exudative detachments of the retina in the acute stage and choroidal thickening, and by demonstrating choroidal thinning in the chronic stage. Treatment of this disease is initially with intravenous corticosteroids, with, if needed, a transition to immunosuppressant drugs for long-term control. Patients with VKH disease can have good final visual outcomes if treated promptly and aggressively.
Collapse
Affiliation(s)
- C Bonnet
- Université Paris Descartes, 75014 Paris, France; Centre Cochin ambulatoire d'ophtalmologie, groupe hospitalier Cochin-Hôtel-Dieu, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | - J-B Daudin
- Centre Cochin ambulatoire d'ophtalmologie, groupe hospitalier Cochin-Hôtel-Dieu, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - D Monnet
- Université Paris Descartes, 75014 Paris, France; Centre Cochin ambulatoire d'ophtalmologie, groupe hospitalier Cochin-Hôtel-Dieu, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - A Brézin
- Université Paris Descartes, 75014 Paris, France; Centre Cochin ambulatoire d'ophtalmologie, groupe hospitalier Cochin-Hôtel-Dieu, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| |
Collapse
|
37
|
Courseau M, Bonnet C, Lautrette G, Gondran G, Fauchais A, Ly K. Sarcoïdose osseuse de forme disséminée pauci-symptomatique : à propos de 2 cas. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, Lancesseur C, Lebras F, Willems E, Tchernonog E, Delarue R, Gressin R, Chauchet A, Gyan E, Cartron G, Bonnet C, Haioun C, Damaj G, Gaulard P, Fornecker L, Ghesquieres H, Tournilhac O, Gomes Da Silva M, Bouabdallah R, Salles G, Bachy E. ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMAS: a PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- G. Fossard
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - F. Broussais
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - I. Coelho
- Hematology; Portuguese Institute of Oncology; Lisbon Portugal
| | - S. Bailly
- Hematology and Cell Therapy Department; Hôpital Estaing; Clermont-Ferrand France
| | | | - E. Toussaint
- Hematology; CHU de Strasbourg; Strasbourg France
| | | | - F. Lebras
- Lymphoid malignancies Unit; CHU Henri Mondor; Créteil France
| | | | | | - R. Delarue
- Hematology; CHU Necker Enfants Malades; Paris France
| | - R. Gressin
- Hematology; CHU Grenoble; Grenoble France
| | | | - E. Gyan
- Hematology; CHU de Tours; Tours France
| | - G. Cartron
- Hematology; CHU de Montpellier; Montpellier France
| | - C. Bonnet
- Hematology; CHU Liège; Liège Belgium
| | - C. Haioun
- Lymphoid malignancies Unit; CHU Henri Mondor; Créteil France
| | - G. Damaj
- Hematology; CHU de Caen; Caen France
| | - P. Gaulard
- Hematology; CHU Henri Mondor; Créteil France
| | - L. Fornecker
- Hematology; CHU de Strasbourg; Strasbourg France
| | - H. Ghesquieres
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - O. Tournilhac
- Hematology and Cell Therapy Department; Hôpital Estaing; Clermont-Ferrand France
| | | | | | - G. Salles
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| | - E. Bachy
- Hematology; Centre Hospitalier Lyon Sud; Pierre Bénite France
| |
Collapse
|
39
|
Godin C, Bonnet C, Vitrat V, Chidiac C, Boibieux A, Rogeaux O, Forestier E, Issartel B, Pavese P. Activité régionale d’infectiologie transversale : un impact possible sur la médecine générale et le parcours des patients. Med Mal Infect 2017. [DOI: 10.1016/j.medmal.2017.03.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
40
|
Bonnet C, Huchet A, Blais E, Benech-Faure J, Trouette R, Vendrely V. PV-0457: Delay between planning and stereotactic radiotherapy for brain metastases: margins still accurate? Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30898-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Barguil Y, Maillaud C, Chèze M, Bonnet C, Garcia F, Lebouvier N, Hnawia E, Nour M. Intoxications par Cerbera manghas L. durant l’année 2016 en Nouvelle-Calédonie. Toxicologie Analytique et Clinique 2017. [DOI: 10.1016/j.toxac.2017.03.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Bonnet C, Rusz J, Hanuška J, Dezortová M, Jírů F, Sieger T, Jech R, Klempíř J, Roth J, Bezdíček O, Serranová T, Dušek P, Uher T, Flammand-Roze C, Hájek M, Růžička E. GABA spectra and remote distractor effect in progressive supranuclear palsy: A pilot study. Rev Neurol (Paris) 2017; 173:225-229. [PMID: 28385472 DOI: 10.1016/j.neurol.2017.03.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 01/11/2017] [Accepted: 03/09/2017] [Indexed: 11/17/2022]
Abstract
Disturbances of the gamma-aminobutyric-acid (GABA) system have been suspected of contributing to the pathophysiology of progressive supranuclear palsy (PSP). The ability to rapidly resolve competitive action decisions, such as shifting the gaze to one particular stimulus rather than another, can be predicted by the concentration of GABA in the region of the frontal cortex relevant to eye movements. For this reason, our study measured GABA levels in seven PSP patients and eight healthy controls, using proton magnetic resonance spectroscopy, and assessed the relationship of these measurements to the remote distractor effect (RDE), an eye-movement paradigm investigating competitive action decisions. No significant differences were found in either frontal-eye-field GABA levels or RDE between PSP patients and controls.
Collapse
Affiliation(s)
- C Bonnet
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic; Department of Neurology, Pitié-Salpêtrière Hospital, AP-HP, 75013 Paris, France
| | - J Rusz
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic; Department of Circuit Theory, Faculty of Electrical Engineering, Czech Technical University, Prague, Czech Republic
| | - J Hanuška
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic; Department of Neurosurgery, Hospital Na Homolce, Prague, Czech Republic
| | - M Dezortová
- MR-unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - F Jírů
- MR-unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - T Sieger
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic; Department of Cybernetics, Faculty of Electrical Engineering, Czech Technical University, Prague, Czech Republic
| | - R Jech
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - J Klempíř
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - J Roth
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - O Bezdíček
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - T Serranová
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - P Dušek
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - T Uher
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic
| | - C Flammand-Roze
- AP-HP, Hospital de Bicêtre, Department of Neurology, 94270 Paris, France
| | - M Hájek
- MR-unit, Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - E Růžička
- Department of Neurology, Center of Clinical Neuroscience, Charles University, First Faculty of Medicine, General University Hospital, Kateřinská 30, Prague 2, 12000 Prague, Czech Republic.
| |
Collapse
|
43
|
Yankam Njiwa J, Costes N, Bouillot C, Bouvard S, Fieux S, Becker G, Levigoureux E, Kocevar G, Stamile C, Langlois JB, Bolbos R, Bonnet C, Bezin L, Zimmer L, Hammers A. Quantitative longitudinal imaging of activated microglia as a marker of inflammation in the pilocarpine rat model of epilepsy using [ 11C]-( R)-PK11195 PET and MRI. J Cereb Blood Flow Metab 2017; 37:1251-1263. [PMID: 27381824 PMCID: PMC5414902 DOI: 10.1177/0271678x16653615] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Inflammation may play a role in the development of epilepsy after brain insults. [11C]-( R)-PK11195 binds to TSPO, expressed by activated microglia. We quantified [11C]-( R)-PK11195 binding during epileptogenesis after pilocarpine-induced status epilepticus (SE), a model of temporal lobe epilepsy. Nine male rats were studied thrice (D0-1, D0 + 6, D0 + 35, D0 = SE induction). In the same session, 7T T2-weighted images and DTI for mean diffusivity (MD) and fractional anisotropy (FA) maps were acquired, followed by dynamic PET/CT. On D0 + 35, femoral arterial blood was sampled for rat-specific metabolite-corrected arterial plasma input functions (AIFs). In multiple MR-derived ROIs, we assessed four kinetic models (two with AIFs; two using a reference region), standard uptake values (SUVs), and a model with a mean AIF. All models showed large (up to two-fold) and significant TSPO binding increases in regions expected to be affected, and comparatively little change in the brainstem, at D0 + 6. Some individuals showed increases at D0 + 35. AIF models yielded more consistent increases at D0 + 6. FA values were decreased at D0 + 6 and had recovered by D0 + 35. MD was increased at D0 + 6 and more so at D0 + 35. [11C]-( R)-PK11195 PET binding and MR biomarker changes could be detected with only nine rats, highlighting the potential of longitudinal imaging studies.
Collapse
Affiliation(s)
| | - N Costes
- 2 CERMEP-Imagerie du Vivant, Lyon, France
| | - C Bouillot
- 2 CERMEP-Imagerie du Vivant, Lyon, France
| | - S Bouvard
- 2 CERMEP-Imagerie du Vivant, Lyon, France.,3 Lyon Neuroscience Research Center, University Claude Bernard Lyon 1, Lyon, France
| | - S Fieux
- 2 CERMEP-Imagerie du Vivant, Lyon, France
| | - G Becker
- 2 CERMEP-Imagerie du Vivant, Lyon, France
| | - E Levigoureux
- 3 Lyon Neuroscience Research Center, University Claude Bernard Lyon 1, Lyon, France.,4 Hospices Civils de Lyon, France
| | | | | | | | - R Bolbos
- 3 Lyon Neuroscience Research Center, University Claude Bernard Lyon 1, Lyon, France
| | - C Bonnet
- 3 Lyon Neuroscience Research Center, University Claude Bernard Lyon 1, Lyon, France
| | - L Bezin
- 3 Lyon Neuroscience Research Center, University Claude Bernard Lyon 1, Lyon, France
| | - L Zimmer
- 2 CERMEP-Imagerie du Vivant, Lyon, France.,3 Lyon Neuroscience Research Center, University Claude Bernard Lyon 1, Lyon, France.,4 Hospices Civils de Lyon, France
| | - A Hammers
- 1 Neurodis Foundation, Lyon, France.,6 Division of Imaging Sciences and Biomedical Engineering, King's College London & Guy's and St Thomas' PET Centre, King's College London, London, UK
| |
Collapse
|
44
|
Bonnet C, Millot I, Achouba A, Czekala M, Thonnelier C, Cottin Y, Husson-Robert B. Survie et réhospitalisation après une première hospitalisation pour insuffisance cardiaque en France : étude de cohorte nationale à partir de la base de données « échantillon généraliste des bénéficiaires » (EGB). Rev Epidemiol Sante Publique 2016. [DOI: 10.1016/j.respe.2016.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
45
|
Esteban Mader M, Bonnet C, Meyronet D, Joly M, Uro-Coste E, Forest F, Guyotat J, Jouvet A, Honnorat J, Ducray F. P08.39 Characteristics of adults’ gliomas with H3-K27M mutations. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Bigot F, Alvarez EC, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Gazzah A, Bonnet C, Michot JM, Marabelle A, Soria JC, Massard C. Identification of new prognostic factors in phase I patients treated by immunotherapy. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Bonnet C, Alvarez EC, Michot JM, Bigot F, Varga A, Gazzah A, Bahleda R, Marabelle A, Hollebecque A, Aspeslagh S, Angevin E, Armand JP, Albiges L, Loriot Y, Postel-Vinay S, Soria JC, Massard C. Patients with metastatic prostate cancer enrolled in phase 1 trials: Outcomes and molecular alterations. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Bonnet C, Cartalat-Carel S, Thomas L, Joubert B, Meyronet D, D’Hombres A, Jouanneau E, Guyotat J, Honnorat J, Ducray F. P08.43 Bevacizumab discontinuation and bevacizumab re-challenge in glioblastoma patients. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now188.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
49
|
Abstract
We have examined the relationship between the reaction time for detecting a sinusoidal grating stimulus and the stimulus variables of spatial frequency, contrast, window size, and uncertainty with respect to spatial frequency. Detection was measured in a two-alternative spatial-forced-choice procedure. The stimuli were horizontal cosine gratings windowed spatially by two-dimensional Gaussians. Spatial frequency was varied from 0.7 to 6.5 cycles deg−1 and contrast was varied from 0.054 to 0.673. The standard deviation of the Gaussian window was fixed in some conditions and the number of cycles presented in each window covaried with spatial frequency. In other conditions, window size was varied, along the vertical axis only, to hold the number of cycles constant. Contrasts were always randomly intermixed, but frequencies were intermixed in some conditions and blocked in others. We confirm previous findings that reaction time increases as spatial frequency increases and decreases as contrast increases. We also confirm and extend the proposal of Rudd that reaction time closely approximates a single function of the product of contrast and the square of the grating period. We consider the implications of these findings for the nature of the physiological mechanisms which govern reaction time.
Collapse
|
50
|
Grange L, Cohen J, Trope S, Poivret D, Bonnet C, Allenet B, Stadelmann C, Chales G, Dachicourt J. OP0139-PARE The First Serious Game Edubiot: A Modern Therapeutic Educational Tool for Adult Patients with Chronic Inflammatory Rheumatic Disease, Treated with Biotherapy. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.2749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|